Introduction
In recent years, there has been increasing interest in using molecular analysis to identify prognostic indicators or therapeutic targets for acute myeloid leukemia (AML). One approach is to identify somatic genomic alterations in leukemic clones. In previous studies, chromosomal alterations that indicate favorable or adverse prognosis were identified by classical G-banding karyotype analysis. These studies determined that translocations involving the retinoic acid receptor or core binding factor proteins indicate a favorable prognosis, a normal karyotype indicates an intermediate prognosis, and a complex karyotype, or lesions involving the MLL gene, indicate an adverse prognosis.
Based on the success of these studies, methods were developed to identify subchromosomal genomic lesions associated with AML. Using microdissection-based comparative genomic hybridization (CGH), chromosomal gains or losses of 5-10 Mb were detected in AML [1, 2, 3 ] . This technique was refined using array based CGH which permits detection of copy number alterations (CNAs) of less than 5 Mb [4] . The development of specific statistical analysis algorithms [5] led to the use of single nucleotide polymorphism (SNP) arrays to investigate CNA in AML. Use of SNP arrays also identified copy number neutral loss of heterozygosity (CNN-LOH) (or acquired uniparental disomy; aUPD) in AML. CNN-LOH may include large regions at the ends of chromosomes (30-90 Mb) or smaller interstitial sequences (2-8 Mb) [6] . Such studies have identified recurring areas of CNA and CNN-LOH in AML.
Single base pair mutations that are relevant to the prognosis of AML have been identified in a number of studies. Such mutations may worsen prognosis (activating FLT3 or KIT mutations) or improve it (NPM1 mutations). The development of high-throughput automated sequencing techniques suggests the possibility of sequencing leukemia genomes to identify novel single nucleotide variants (SNVs) or small genomic dupli-Purpose of review Acute myeloid leukemia (AML) is a heterogeneous group of clonal myeloid malignancies. With a few exceptions, response to treatment is unsatisfactory and prognosis is poor. Studies indicate that specific cytogenetic abnormalities, identified by classical G-banding, correlate with prognosis. These findings advanced the ability to predict outcome and to tailor treatments in AML. These studies also suggested that a more detailed analysis of somatic genomic mutations might extend these advances.
Recent findings
New technologies, including DNA arrays and automated sequencing, have improved detection of subtle, acquired genomic alterations. DNA array based screening approaches permit detection of copy number alterations (CNAs) of less than 5 Mb in size. Subchromosomal copy number neutral loss of heterozygosity (CNN-LOH) can also be detected using approaches that take advantage of single nucleotide polymorphisms in the human genome. However, identification of single nucleotide variants in leukemic clones still requires targeted or massive sequencing approaches. Summary Recent studies suggest that CNAs and CNN-LOH occur frequently in AML. Recurring abnormalities have been identified which may be relevant to disease pathogenesis. However, larger studies will be required to determine the relevance of these alterations to prognostic prediction or therapeutic targeting. cations. Although potentially powerful, the current technology requires substantial effort for each sample [7 ] .
Copy number alterations in acute myeloid leukemia
Recent studies, using CGH or SNP microarrays, have identified a recurring set of acquired CNA associated with AML. The potential significance of these results for the pathogenesis of myeloid malignancy is suggested by the presence of a number of tumor suppressor genes in areas of loss and oncogenes in areas of genomic gain.
Studies of CNA in normal karyotype AML are of interest to further define prognostic groups in this heterogeneous, intermediate prognosis category. In one study, Akagi et al. [8] identified CNA in 24% (nine of 38) normal karyotype AML samples using 250K SNP arrays. Areas of genomic loss included genes encoding tumor suppressors such as NF1 (17q; encoding neurofibromin), EVT6 (12p; encoding Tel) or CDKN2A or 2B (9p; encoding cyclin-dependent kinase inhibitor). They also found recurrent gains in chromosome 8 in a region including the MYC gene. Consistent with these results, mRNA expression studies documented decrease in Nf1, Tel, and Cdki and increase in c-myc. In another study, Walter et al. [9 ] investigated CNA in 86 newly diagnosed AML patients, including 40% with normal karyotype. They found that 24% of the normal karyotype patients had CNA (in comparison to 40% of patients with various abnormalities in karyotype identified by G-banding). These authors found 50 recurrent CNA of less than 5 Mb with losses more common than gains. Regions with leukemia or cancer-associated genes were statistically overrepresented in these studies, including 12p, 17q, 5q, 7q, and 16q. Amplification of 8q was identified as were amplification of 11q (including the MLL gene), 19q, and 21q.
AML with complex karyotype is another subgroup for which CNA studies are potentially informative. Determination of chromosomal gains or losses by conventional G-banding is difficult in samples with multiple translocations. Rucker et al. [10] investigated 60 AML samples with complex karyotype using a custom CGH array. The found CNA in 100% of samples with losses greater than gains. The most common losses involved 5q, 17p (including TP53), and 7q, and the most common gains were in 11q and 8q. Less common losses included 16q, 17q, and 18q. In this study, gains or losses of chromosomal material also correlated with altered gene expression in the involved regions. Kim et al. studied 19 cases of complex karyotype AML using microdissection-based CGH [1]. They found CNA in nine of these cases, consistent with the lower sensitivity of this method. However, they also identified most frequent losses in 5q and 17p and most frequent gains including 8q and 11q. Therefore, both of these studies suggest that complex karyotype AML is characterized by increased c-myc and Mil and decreased p53.
Although acute promyelocytic leukemia (APL) has a relatively good prognosis, some patients with APL respond to treatment more poorly than anticipated, despite the absence of additional cytogenetic markers. A group of 47 patients with t(15;17) APL were studied by Akagi et al. [11 ] using SNP microarrays. They found that 60% of these patients had no CNA. Of those with abnormality, eight of 11 had amplification involving chromosome 8. Losses were less frequent (seven total, with only 7q appearing in more than one case). They also investigated FLT3 mutation status and found activating FLT3 mutations only in samples without CNA. Therefore, the patients fell into three groups: 8þ, Flt3 mutant, and no other abnormalities. These groups will be of interest for future prognostic studies. Karnan et al. [12] investigated APL patients using CGH microarrays. In this study of 30 APL patients, 16 were found to have CNA. This included recurrent losses in 1p, 2p, 16p, and 17p and gains in 8p, 8q, and 13q. In contrast to the previous study, these investigators found no difference in FLT3 mutation rate between patients compared with those without CNA. As both of these studies were relatively small, follow-up with larger cohorts will be required.
Although AML with mutation of genes encoding core binding factors [t(8;21) or inv (16) ] indicates a relatively favorable prognosis, some of these patients also do more poorly than expected. Akagi et al. [13 ] used highdensity SNP arrays to study 48 newly diagnosed AML patients with t(8;21) as the only abnormality identified by conventional cytogenetics. They found no CNA in 67% (group A) and CNA in 33% (group B). As KIT mutation is associated with poor prognosis in t(8;21) AML, sequence analysis was performed. The authors identified activating KIT mutations in both groups, but concurrent amplification and mutation in group B.
Correlation between copy number alterations and prognosis in myelodysplastic syndrome and acute myeloid leukemia
The significance of identifying CNA in AML would be increased by determining a correlation with prognosis. At present, most studies involve relatively small numbers of patients and most of the recurrent gains or losses are individually present at low frequency. However, Walter et al. [9 ] found that CNA was more common in M6 and M7 AMLs in comparison to normal karyotype AML, suggesting correlation of CNA with relatively adverse prognosis. They also found that patients with 17q or 21q deletion had worse overall survival. However, the total number of CNA per patient did not correlate with survival, suggesting specific gains or losses might be driving the prognosis. Karnan et al. [12] found that CNA did not worsen remission rates or outcome in APL, but Akagi et al. [13 ] found CNA worsened prognosis in t(8;21) AML. The latter result is complicated by the fact that KIT mutations were slightly more common in the group with CNA.
Gohring et al. [14] used array-based CGH to study pediatric patients with various congenital bone marrow failure disorders. They found correlation between CNA and progression to myelodysplastic syndrome (MDS)/AML. These results suggest the possible role of screening such patients for CNA to predict progression and determine the timing of interventions such as stem cell transplant.
Copy number neutral loss of heterozygosity in myelodysplastic syndrome and acute myeloid leukemia
The use of SNP microarray technology to identify CNA led to the realization that acquired CNN-LOH (or aUPD) is frequent in AML. Raghavan et al. [15] studied 64 subjects with newly diagnosed AML using a 10K SNP microarray and identified CNN-LOH in 20% of the patients. These studies identified recurrent regions of CNN-LOH in AML on chromosomes 11p, 11q, 6p, and 9q. These authors also investigated CNN-LOH at relapse in AML [16 ] . They found aUPD in 40% of AML samples at relapse, with the most common abnormality on 13q.
Similar to CNA, CNN-LOH is also common in normal karyotype AML. Akagi et al. [8] found that 32% of patients with normal karyotype by G-banding cytogenetics exhibited CNN-LOH. The median size of the areas of LOH in this study was À31 Mb. Recurrent regions of CNN-LOH included 1p, 6p, 8q, 13q, and 19p. Walter et al. [9 ] also analyzed patients with normal karyotype AML for CNN-LOH. Comparing leukemia samples with normal tissue for 34 patients, they found CNN-LOH in only 15%. Additional studies with larger cohorts will be required to further clarify the frequency and significance of aUPD in normal karyotype AML. As aUPD requires a recombination event, association between CNN-LOH and microsatellite instability was investigated by Serrano et al. [17 ] . In this study, 22 samples from patients with normal karyotype AML were analyzed. Of the nearly 23% patients with CNN-LOH, 60% exhibited microsatellite instability in comparison with only 17% without CNN-LOH.
Studies of CNN-LOH in patients with t(15;17) APL were also performed by Akagi et al. [11 ] . They found aUPD in 15% of all the APL patients, including recurrent CNN-LOH involving 10q, 11p, and 19q. However, this group found CNN-LOH in only 8% of patients with newly diagnosed t(8;21) AML [13 ] . Regions involved in aUPD included 11p, 11q, and 6p. These studies identify 6p, 13q, and 11p as common, recurrent regions of CNN-LOH in AML across multiple studies. This includes forms of AML with both favorable and unfavorable prognosis.
Correlation between copy number neutral loss of heterozygosity and mutation
In most forms of cancer, LOH is generally associated with loss of a copy of a tumor suppressor gene. Because some of the recurrent chromosomal regions of CNN-LOH in AML include genes that are involved in leukemiaassociated mutations, investigations were performed to determine whether the leukemic clone is homozygous for the mutation. This would suggest that two copies of the mutant allele resulted in a competitive advantage and outgrowth of the clone. Fitzgibbon et al.
[18] studied 13 patients with AML and CNN-LOH for the presence of two alleles of leukemia-associated mutations of WT1 (11 p), FLT3 (13q), CEBPA (19q), and RUNX1 (21q). These genes are found at recurrent sites of CNN-LOH in AML. These investigators documented homozygous mutation of FLT3 (four of four), WT1 (one of three), and RUNX1 (one of one). Raghavan et al. [16 ] found homozygosity for internal tandem duplication (ITD) FLT3 in AML samples at relapse. CNN-LOH with homozygous ITD-FLT3 was also found in studies of normal karyotype AML [8, 9 ] , although this association was not found in a study of APL [11 ] . Raghavan et al. [16 ] found CNN-LOH of 19q was associated with two copies of a mutant form of CEBPA in a group of AML patients at diagnosis. Additional studies will be required to determine the statistical significance of these associations between CNN-LOH and homozygous mutation of leukemiaassociated genes and the impact of this concurrence on prognosis.
Single nucleotide variants in myelodysplastic syndrome and acute myeloid leukemia
The next logical level of analysis of AML genomes would be identification of acquired SNVs. As parallel sequencing of genomic DNA from the leukemia clone and unaffected tissues is required; this is a very labor-intensive endeavor, even with automated sequencing technology. One such study was recently reported by Mardis et al. [7 ] , in which the authors sequenced 98% of the genome from a leukemic clone and normal skin of a patient with M1-AML. Twelve acquired somatic mutations were identified in coding sequences of genes and 52 in conserved or regulatory genomic regions. Targeted sequencing identified four of these 64 mutations in at least one sample from 188 additional AML patients. This included mutation in NRAS and NPM1 (previously described), and IDH1 and a nongenic mutation in a conserved sequence Genomic analysis of acute myeloid leukemia Eklund 77 (not previously described). These studies indicate both the power and difficulties with this approach.
Conclusion
Incorporation of classical G-banding cytogenetic analysis has altered prognostic assessment in AML. Technological advances permit a more detailed analysis of genomic losses or gains, and CNN-LOH. Combining mutation analysis with CNN-LOH studies may be particularly informative for prognostic considerations. Initial studies using these techniques have identified a number of recurrent chromosomal regions involved in CNA and CNN-LOH. Very early studies with massive parallel genomic sequencing indicate that recurrent SNVs may also be identified using this approach.
At present, assessment of CNA or CNN-LOH can be considered of potential importance to identifying additional prognostic indicators in AML. Further studies on larger populations will be required to determine the significance of specific abnormalities for prognosis or pathogenesis of AML. Of particular interest will be investigations to determine whether aUPD with two copies of a gene containing a leukemia-associated mutation worsens the prognosis in comparison to heterozygosity for the mutation. Genomic sequencing at this point is a research tool, with further technical developments necessary to accumulate population data and assess the usefulness of identifying large numbers of leukemia-associated SNVs.
